Docs Embrace Takeda’s Eohilia, Creating Competition for Sanofi, Regeneron’s Blockbuster Dupixent

1. Eohilia Rejection: The FDA rejected Takeda's Eohilia (formerly TAK-721) in 2021 for the treatment of chronic inflammatory disease eosinophilic esophagitis.
2. Competition for Dupixent: Docs are embracing Eohilia, creating competition for Sanofi and Regeneron's blockbuster drug Dupixent.
3. Market Impact: The acceptance of Eohilia by doctors may disrupt the market dominance of Dupixent in the treatment of eosinophilic esophagitis.
4. Pharmaceutical Insights: Spherix Global Insights provides market analysis and expert advice across various therapeutic areas, including dermatology, gastroenterology, rheumatology, and more.